Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Equillium Inc (NQ: EQ )

0.7625 -0.0030 (-0.39%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,682
Open 0.7803
Bid (Size) 0.7600 (5)
Ask (Size) 0.7993 (6)
Prev. Close 0.7655
Today's Range 0.7501 - 0.7999
52wk Range 0.4500 - 3.250
Shares Outstanding 34,414,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Equillium Maintains Rights to Itolizumab Following Ono Partnership
From Equillium Inc.
Via Business Wire

Performance

YTD
+3.84%
+3.84%
1 Month
-19.75%
-19.75%
3 Month
+7.24%
+7.24%
6 Month
-57.64%
-57.64%
1 Year
+52.50%
+52.50%

More News

Read More
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
From Equillium, Inc.
Via Business Wire
EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights
From Equillium Inc.
Via Business Wire
Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
From Equillium, Inc.
Via Business Wire
Equillium to Participate in Upcoming Investor Conferences
From Equillium, Inc.
Via Business Wire
Equillium to be included in the Russell Microcap® Index
From Equillium, Inc.
Via Business Wire
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Equillium, Inc.
Via Business Wire
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Gold Down 1%; Bath & Body Works Shares Tumble After Q1 Results
Via Benzinga
US Stocks Lower; Donaldson Earnings Beat Views
Via Benzinga
Topics Earnings
Exposures Financial
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
From Equillium Inc.
Via Business Wire
Equillium to Present at the Jefferies Global Healthcare Conference
From Equillium, Inc.
Via Business Wire
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
From Equillium, Inc.
Via Business Wire
EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
From Equillium Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.